Roth Capital Issues Pessimistic Estimate for MNMD Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Equities research analysts at Roth Capital lowered their Q3 2025 EPS estimates for Mind Medicine (MindMed) in a report released on Tuesday, November 19th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0.35) per share for the quarter, down from their prior forecast of ($0.34). The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.25) per share. Roth Capital also issued estimates for Mind Medicine (MindMed)'s FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.61) EPS, FY2027 earnings at $1.27 EPS and FY2028 earnings at $4.67 EPS.

Other research analysts have also issued research reports about the company. Canaccord Genuity Group dropped their target price on Mind Medicine (MindMed) from $16.00 to $14.00 and set a "buy" rating for the company in a research report on Monday, September 16th. Leerink Partnrs upgraded Mind Medicine (MindMed) to a "strong-buy" rating in a report on Friday, October 11th. Leerink Partners initiated coverage on Mind Medicine (MindMed) in a research report on Monday, October 14th. They issued an "outperform" rating and a $20.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $55.00 target price on shares of Mind Medicine (MindMed) in a research report on Monday, November 11th. Nine analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $25.38.

Mind Medicine (MindMed) Trading Up 6.6 %

Shares of MNMD stock traded up $0.47 during trading hours on Friday, reaching $7.56. 1,016,000 shares of the stock were exchanged, compared to its average volume of 1,451,032. The firm has a market capitalization of $554.37 million, a price-to-earnings ratio of -3.38 and a beta of 2.48. Mind Medicine has a 12-month low of $2.75 and a 12-month high of $12.22. The company's 50-day moving average price is $6.41 and its 200-day moving average price is $7.16. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling at Mind Medicine (MindMed)

In other news, CEO Robert Barrow sold 19,771 shares of the firm's stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $5.98, for a total value of $118,230.58. Following the completion of the sale, the chief executive officer now owns 545,772 shares of the company's stock, valued at $3,263,716.56. This trade represents a 3.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dan Karlin sold 6,871 shares of the business's stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $5.98, for a total value of $41,088.58. Following the transaction, the insider now owns 344,656 shares in the company, valued at approximately $2,061,042.88. This trade represents a 1.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,994 shares of company stock valued at $173,384. 2.26% of the stock is currently owned by insiders.

Institutional Trading of Mind Medicine (MindMed)

Several large investors have recently bought and sold shares of the stock. Tri Locum Partners LP lifted its holdings in shares of Mind Medicine (MindMed) by 0.6% during the second quarter. Tri Locum Partners LP now owns 382,055 shares of the company's stock worth $2,755,000 after purchasing an additional 2,459 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Mind Medicine (MindMed) by 22.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,226 shares of the company's stock worth $126,000 after buying an additional 4,079 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in Mind Medicine (MindMed) by 24.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 35,508 shares of the company's stock valued at $256,000 after acquiring an additional 6,890 shares during the period. State Street Corp boosted its holdings in shares of Mind Medicine (MindMed) by 0.5% in the 3rd quarter. State Street Corp now owns 1,814,829 shares of the company's stock valued at $10,326,000 after acquiring an additional 9,782 shares during the last quarter. Finally, Bridgewealth Advisory Group LLC acquired a new stake in shares of Mind Medicine (MindMed) in the second quarter worth $72,000. Hedge funds and other institutional investors own 27.91% of the company's stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.